EUCTR2013-000723-14-FR进行中（未招募）1 期
A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia
Amgen Inc.0 个研究点目标入组 900 人开始时间: 2015年6月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Subject has provided written informed consent.
- •2) Male or female, = 18 to = 80 years of age at signing of informed consent.
- •3) Type 2 diabetes, defined as receiving pharmacologic treatment for type 2 diabetes for = 6 months prior to screening, with stable diabetes therapy prior to randomization to IP and not expected to change during the duration of study participation. Stable diabetes therapy is defined as no new agents added, no dose change of any oral antihyperglycemic drug within 2 months, and daily insulin dose not changed by > 25% and > 25 units within 1 month prior to randomization
- •4) Lipid-lowering therapy status (eg, not receiving any therapy or receiving any statin, ezetimibe, bile-acid sequestering resin, stanols, probucol, omega 3 fatty acids or niacin) must be unchanged for = 4 weeks prior to LDL-C screening.
- •5) Subjects receiving statin therapy at screening must have a fasting LDL-C at screening of = 100 mg/dL (2.6 mmol/L) as determined by central laboratory.
- •6) Subjects not receiving statin therapy at screening must have a fasting LDL-C at screening of = 130 mg/dL (3.4 mmol/L) as determined by central laboratory.
- •7) Fasting triglycerides = 400 mg/dL (4.5 mmol/L) by central laboratory at screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 700
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •1) Receiving 20 mg atorvastatin QD monotherapy for approximately 16 weeks is medically contraindicated or inappropriate based on opinion of investigator.
- •2) NYHA III or IV heart failure, or last known left ventricular ejection fraction < 30%.
- •3) Uncontrolled cardiac arrhythmia defined as recurrent and highly symptomatic ventricular tachycardia, atrial fibrillation with rapid ventricular response, or supraventricular tachycardia that is not controlled by medications, in the past 6 months prior to randomization.
- •4) Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 6 months prior to randomization.
- •5) Planned cardiac surgery or revascularization within 6 months after randomization.
- •6) Type 1 diabetes or poorly controlled type 2 diabetes (HbA1c > 10.0 % at screening and at lipid stabilization or not on stable pharmacologic therapy for type 2 diabetes. Stable therapy is defined as no new agents added, no dose change of any oral antihyperglycemic drug within 2 months, and daily insulin dose not changed by > 25% and > 25 units within 1 month prior to randomization.
- •7) Uncontrolled hypertension defined as sitting systolic blood pressure (SBP) > 160 mmHg or diastolic BP (DBP) > 100 mmHg
- •8) Subject is unwilling or unable to discontinue between start of lipid stabilization with 20 mg/day atorvastatin and end of study (week 12 for QM and week 14 for Q2W subjects) the following drugs or supplements: red yeast rice, niacin (> 200 mg/day), > 1000 mg/day omega-3 fatty acids (eg, Docosahexaenoic acid [DHA] and eicosapentaenoic acid [EPA], prescription and non-prescription combined), and all other prescription lipid-regulating drugs (eg, fibrates and derivatives, ezetimibe, bile-acid sequestering resin, stanols, or probucol) except study-provided atorvastatin.
- •9) Subject has taken a cholesterylester transfer protein (CETP) inhibitor in the last 12 months prior to randomization, such as: anacetrapib, dalcetrapib or evacetrapib.
- •10) Treatment in the last 2 months prior to screening and lipid stabilization assessments with any of the following drugs: systemic cyclosporine, systemic steroids (eg, intravenous [IV], intramuscular [IM], or oral [PO] administration), vitamin A derivatives and retinol derivatives for the treatment of dermatologic conditions (eg, Accutane); (Note: vitamin A in a multivitamin preparation is permitted).
- •11) Hyperthyroidism or hypothyroidism as defined by thyroid stimulating hormone (TSH) below the lower limit of normal (LLN) or > 1.5 times the upper limit of normal (ULN), respectively, at screening.
- •12) Moderate to severe renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 at screening.
- •13) Persistent active liver disease or hepatic dysfunction, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times the ULN as determined by central laboratory analysis at screening or lipid stabilization assessments.
- •14) Creatine kinase (CK) > 3 times the ULN at screening or lipid stabilization assessments.
- •15) Known active infection or major hematologic, renal, metabolic, gastrointestinal or endocrine dysfunction (except diabetes).
- •16) Deep vein thrombosis or pulmonary embolism within 3 months prior to randomization.
- •17) Female subject who has either (1) not used (an) acceptable method(s) of birth control (see protocol) for at least 1 month prior to screening or (2) is not w
研究者
相似试验
进行中（未招募）
1 期
Study to determine the adequate dose of a new medicine omecantiv mecarbil compared to placebo in patients with a heart condition whereby the ability of the heart to pump enough blood to meet the body’s need at all times is reduced.Chronic Heart Failure and Left Ventricular Systolic DysfunctionMedDRA version: 17.0Level: PTClassification code 10063083Term: Chronic left ventricular failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2012-000327-40-DEAmgen Inc.570
进行中（未招募）
不适用
A research study to find out if people with Primary Generalized Tonic-Clonic Seizures, by taking perampanel in addition to their normal epilepsy medicine(s), have fewer seizures and feel better. Either perampanel (real medicine) or placebo (pretend medicine that looks the same as the real medicine) will be given in addition to ordinary epilepsy medicines. Who gets which is decided randomly. There is an option to continue into the Follow-on (Extension) Phase of the study.Primary Generalized Tonic-Clonic SeizuresMedDRA version: 16.1Level: HLTClassification code 10018101Term: Generalised tonic-clonic seizuresSystem Organ Class: 100000004852EUCTR2011-000265-12-ATEisai Limited164
进行中（未招募）
1 期
A Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events when Evolocumab (AMG 145) is used in combination With Statin Therapy In Patients with Clinically Evident Cardiovascular DiseaseDyslipidemiaMedDRA version: 19.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 19.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2012-001398-97-DKAmgen Inc27,500
进行中（未招募）
1 期
A study investigating the use of Omecamtiv Mecarbil on subjects with heart failureChronic Heart Failure With Reduced Ejection FractionMedDRA version: 19.0Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 100000004849EUCTR2016-002299-28-ESAmgen Inc8,232
进行中（未招募）
不适用
Study to determine the adequate dose of a new medicine omecantiv mecarbil compared to placebo in patients with a heart condition whereby the ability of the heart to pump enough blood to meet the body’s need at all times is reduced.EUCTR2012-000327-40-ITAmgen Inc.420